The recent finding that platelet inhibitors reduce hepatitis B associated experimental HCC[40] has led to new interest in the use of aspirin and other platelet inhibitors in HCC prevention, as in colon cancer prevention[41]. This evidence concerns the gene PPIB and hepatocellular carcinoma.